What are Cytek Biosciences, Inc.'s profit margins?

Cytek Biosciences, Inc. (CTKB) runs a 51.7% gross margin and a -21.5% operating margin, with a -36.2% net margin.

Where do Cytek Biosciences, Inc.'s ratios come from?

Every ratio is computed from Cytek Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Cytek Biosciences, Inc. CTKB Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Profitability
Gross margin	51.7%-3.2pp	51.8%-3.6pp	53.5%-1.5pp	54.4%-0.5pp	54.9%-0.5pp
Operating margin	-21.5%—	-20%—	——	——	——
Net margin	-36.2%—	-33%—	——	——	——
Returns
Return on equity	-20.9%—	-18%—	——	——	——
Return on invested capital	-14.4%—	-12.6%—	——	——	——
Efficiency
Asset turnover	0.4×0.0×	0.4×0.0×	0.4×0.0×	0.4×0.0×	0.4×0.0×
Liquidity
Current ratio	4.7×-0.9×	5×-0.8×	5.2×-1.0×	5.2×-2.1×	5.6×-1.4×
Leverage
Debt-to-equity	0.1×0.0×	0.1×0.0×	0×0.0×	0×0.0×	0×0.0×
Per Share
Book value per share	$2.55-13.9%	$2.68-11.7%	$2.97+2.2%	$2.97+0.5%	$2.96-1.4%
Valuation
Market capitalization	$577.27M+54.5%	$645.72M-22.8%	$441.47M-39.4%	$409.11M-44.0%	$513.67M-41.4%
Price / sales	2.8×+0.9×	3.2×-1.0×	2.2×-1.4×	2.1×-1.6×	2.6×-1.8×
Price / book	1.8×+0.8×	1.9×-0.2×	1.2×-0.7×	1.1×-0.8×	1.4×-0.9×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Cytek Biosciences, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Cytek Biosciences, Inc.'s profit margins?: Cytek Biosciences, Inc. (CTKB) runs a 51.7% gross margin and a -21.5% operating margin, with a -36.2% net margin.
Where do Cytek Biosciences, Inc.'s ratios come from?: Every ratio is computed from Cytek Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.